Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (SNDX) had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $34.00. They now have a "buy" rating on the stock.
Syndax Pharmaceuticals (SNDX) had its price target lowered by Mizuho from $45.00 to $43.00. They now have an "outperform" rating on the stock.
Syndax Pharmaceuticals (SNDX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $40.00 price target on the stock, down from $48.00.
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset [Yahoo! Finance]